We are live on ! Find out more
BIOS

BioPlus Acquisition Corp. Class A Ordinary Shares
BIOS

Delisted

BIOS was delisted on the 6th of October, 2023.

Back to rankings

61 hedge funds and large institutions have $231M invested in BioPlus Acquisition Corp. Class A Ordinary Shares in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more capital invested

Capital invested by funds: $218M → $231M (+$12.6M)

9% less funds holding

Funds holding: 67 → 61 (-6)

21% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 14

50% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 10

Holders
61
Holders Change
-6
Holders Change %
-8.96%
% of All Funds
0.97%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
11
Reduced
14
Closed
10
Calls
$104K
Puts
–
Net Calls
+$104K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
WCMNY
Westchester Capital Management (New York)
New York
+$11.8M
2
PMAM
Picton Mahoney Asset Management
Ontario, Canada
+$10.4M
3
MC
Meteora Capital
Florida
+$9.42M
4
AC
Aristeia Capital
Connecticut
+$9.01M
5
BFM
Boothbay Fund Management
New York
+$7.9M

Top Sellers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
-$15.2M
2
Millennium Management
Millennium Management
New York
-$10.3M
3
SCM
Saba Capital Management
New York
-$7.77M
4
Marshall Wace
Marshall Wace
United Kingdom
-$5.16M
5
TCA
Taconic Capital Advisors
New York
-$5.14M

BIOS Hedge Fund Activity: Q1 2023 in Review

61 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) for Q1 2023, worth a combined $231M — up 5.8% from $218M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of BIOS and 5 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 11 added.

The largest buyer was Westchester Capital Management (New York), adding an estimated $11.8M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $15.2M sold.

  • 61 institutional investors held BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) as of Q1 2023, down from 67 in Q4 2022.
  • Funds reported $231M of BioPlus Acquisition Corp. Class A Ordinary Shares stock for Q1 2023, up 5.8% quarter-over-quarter.
  • 5 funds opened new BioPlus Acquisition Corp. Class A Ordinary Shares positions in Q1 2023 and 10 closed out, a net change of -5 holders.
  • The largest BioPlus Acquisition Corp. Class A Ordinary Shares buyer in Q1 2023 was Westchester Capital Management (New York), an estimated $11.8M added.
  • The largest BioPlus Acquisition Corp. Class A Ordinary Shares seller in Q1 2023 was Highbridge Capital Management, an estimated $15.2M sold.

Based on aggregated 13F filings for Q1 2023.